Won First Place in the Judges' Choice Category at the Tokyo-Silicon Valley MedTech Launchpad
FerroptoCureAt the Tokyo-Silicon Valley MedTech Launchpad Virtual Demo Day 2026, FerroptoCure was awarded “Judges’ Choice 1st Place” among the 14 Japanese medtech startups that participated. At this international pitch event attended by global investors and healthcare professionals, the company was highly praised for its technological capabilities and growth potential in the global market.
This program is operated with the support of the Tokyo Metropolitan Government as an acceleration program designed to assist Japanese medtech companies in entering the U.S. market.
Moving forward, FerroptoCure aims to further accelerate the research and development of innovative cancer therapies utilizing ferroptoxis, while expanding collaborations with domestic and international companies and research institutions to grow into a drug discovery company with a strong presence in the global market. We remain committed to advancing drug discovery to deliver new treatment possibilities to patients around the world.
